Pharmaceutical Research

, Volume 26, Issue 11, pp 2471–2477 | Cite as

Effects of Selective Androgen Receptor Modulator (SARM) Treatment in Osteopenic Female Rats

  • Jeffrey D. Kearbey
  • Wenqing Gao
  • Scott J. Fisher
  • Di Wu
  • Duane D. Miller
  • James T. DaltonEmail author
Research Paper



Although androgens are known to protect bone, side effects and poor oral bioavailability have limited their use. We previously reported that S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (S-4) is a potent and tissue-selective androgen receptor modulator (SARM). This study was designed to evaluate the skeletal effects of S-4 in an osteopenic model.


Aged female rats were gonadectomized or sham operated on day 1 and assigned to treatment groups. Dosing was initiated on day 90 and continued daily until day 210. Whole animal bone mineral density (BMD), body weight, and fat mass were determined by dual energy x-ray absorptiometry (DEXA). Regional analysis of excised bones was performed using DEXA or computed tomography. Femur strength was evaluated by 3-point bending.


S-4 restored whole body and lumbar vertebrae (L5-L6) BMD to the level of intact controls. Significant increases in cortical bone quality were observed at the femoral midshaft, resulting in increased load bearing capacity.


S-4 demonstrated partial/complete recovery of bone parameters to age-matched intact levels. Increased efficacy observed in cortical bone sites is consistent with reported androgen action in bone. The ability of S-4 to promote bone anabolism, prevent bone resorption, and increase skeletal muscle mass/strength positions these drugs as promising new alternatives for the treatment of osteoporosis.


androgens & SARMs bone densitometry bone QCT mechanical loading rodent 



The authors would like to thank Dr. Juhyun Kim, Dr. Jun Yang, Dr. Victor Shen, and Dr. Mitch Steiner for their technical assistance and advice.


  1. 1.
    Rubinand MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am. 2003;32:285–307.CrossRefGoogle Scholar
  2. 2.
    Vanderschuerenand D, Vandenput L. Androgens and osteoporosis. Andrologia. 2000;32:125–30.CrossRefGoogle Scholar
  3. 3.
    Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull. 2003;26:1563–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Leaand CK, Flanagan AM. Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat. Am J Physiol. 1998;274:E328–35.Google Scholar
  5. 5.
    Tobias JH, Gallagher A, Chambers TJ. 5 alpha-Dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol. 1994;267:E853–9.PubMedGoogle Scholar
  6. 6.
    Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, et al. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24:328–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther. 2003;304:1334–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Kearbey JD, Wu D, Gao W, Miller DD, Dalton JT. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica. 2004;34:273–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Wronski TJ, Cintron M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 1988;43:179–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Ott S. Osteoporosis and Bone Physiology. 1998.Google Scholar
  11. 11.
    Lipsitz LA, Nakajima I, Gagnon M, Hirayama T, Connelly CM, Izumo H, et al. Muscle strength and fall rates among residents of Japanese and American nursing homes: an International Cross-Cultural Study. J Am Geriatr Soc. 1994;42:953–9.PubMedGoogle Scholar
  12. 12.
    Iwaniec UT, Samnegard E, Cullen DM, Kimmel DB. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1–84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone. 2001;29:352–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Samnegard E, Akhter MP, Recker RR. Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats. Bone. 2001;28:414–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Samnegard E, Iwaniec UT, Cullen DM, Kimmel DB, Recker RR. Maintenance of cortical bone in human parathyroid hormone(1–84)-treated ovariectomized rats. Bone. 2001;28:251–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, et al. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol. 2003;63:211–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jeffrey D. Kearbey
    • 1
    • 2
  • Wenqing Gao
    • 1
  • Scott J. Fisher
    • 1
  • Di Wu
    • 1
  • Duane D. Miller
    • 2
    • 3
  • James T. Dalton
    • 1
    • 2
    Email author
  1. 1.College of Pharmacy, Division of PharmaceuticsThe Ohio State UniversityColumbusUSA
  2. 2.GTx, Inc.MemphisUSA
  3. 3.Graduate Health Sciences Center, College of Pharmacy, Department of Pharmaceutical SciencesUniversity of TennesseeMemphisUSA

Personalised recommendations